Novartis
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Novartis
Apr 30, 2024, 16:14 |
Stories
Pat Garcia-Gonzalez: Ethiopia Revisited - on the strength of the human spirit and progress in the face of adversity
Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared on LinkedIn: "Earlier last week,…
Apr 12, 2024, 11:49 |
Drugs
Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492
Vasileios Askoxylakis, Vice President, Global Head Oncology Early Clinical Development at Servier, shared on LinkedIn: "Very…
Apr 7, 2024, 07:20 |
Insight
Wafik El-Deiry: Dr. Alice Shaw speaks about directions in ADC’s in cancer therapy at AACR 2024
Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University, recently posted on LinkedIn:…
Apr 5, 2024, 18:16 |
Insight
Timothée Olivier: NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert!!
Timothée Olivier, Medical Oncologist at HUG - Geneva University Hospitals, shared a post by the…
Apr 2, 2024, 21:19 |
Career
Lucy Setian: I’m starting a new role as the Director of Patient Experience Strategy and Solutions, Hematology at Novartis!
Lucy Setian, Director of Patient Experience Strategy and Solutions, Hematology at Novartis, made the following…
Mar 21, 2024, 10:46 |
Insight
Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence - UCLA Health
Drug regimen significantly improves invasive disease-free survival for patients with stage 2 or 3 HR-positive,…
Mar 18, 2024, 23:27 |
Blog
Ivana Cattaneo: One week ago five new global teams have been selected to receive up to $25m each over five years to tackle some of cancer's toughest challenges
Ivana Cattaneo, Executive Director Therapeutic Area Advocacy and Precision Medicine at Novartis, shared the following…
Feb 21, 2024, 20:57 |
Blog
Shreeram Aradhye: I have the privilege of hearing directly from patients and what really matters to them when it comes to their treatment
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis made the following post on…
Feb 12, 2024, 16:02 |
Blog
Jean-Paul Kress: MorphoSys announced that it has entered into a business combination agreement to be acquired by Novartis
Jean-Paul Kress, CEO of MorphoSys, shared on LinkedIn: "Last week, MorphoSys announced that it has…
Jan 25, 2024, 14:14 |
Insight
Hung Trinh: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
Hung Trinh, Director of Process Development and MFG Science and Technology at Vyriad, posted on…
1
2
All:
18
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube